Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer

NCT07067255 is registered in ClinicalTrials.gov with Essen Biotech as lead sponsor.

NCT NCT07067255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07067255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
Lead sponsor
Essen Biotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 29, 2025
Completion date
December 28, 2029
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, ovarian cancer stage iv, ovarian carcinoma, ovarian sarcoma